During weight loss, bimagrumab leads to an increase in lean mass, while apitegromab slows the loss of lean mass.
From The Ultimate Peptide Stack? Gain Muscle, Lose Fat! · videoSee the scientific wording
Bimagrumab increases lean mass during weight loss, while apitegromab reduces the rate of lean mass loss during weight loss.
Very strong evidence
Randomized trials3 high-quality studies support this claim.
What the research says
3 studies reviewedSupporting (3)
Randomized Controlled TrialHuman2026
Bimagrumab helped people keep their muscle while losing weight, unlike other treatments that caused more muscle loss. But this study didn't test apitegromab, so we can't say how it compares.
Randomized Controlled TrialHuman2026
The study shows that apitegromab helps people keep more muscle while losing weight, which matches part of the claim. It doesn't test bimagrumab, so we can't say for sure about that drug, but what it does show supports the part about apitegromab.
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
Randomized Controlled TrialHuman2021
The study shows that bimagrumab helps people gain muscle while losing weight, which matches part of the claim. But it doesn't say anything about apitegromab, so we can't confirm that part.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A drug that blocks myostatin or activin signals tells muscle cells to build more protein and stop breaking down, so muscle mass stays the same or grows even when the body is losing weight. At the same time, fat tissue breaks down more because the same signals that suppress muscle also suppress fat burning, so blocking them helps the body burn fat without losing muscle.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 3 supporting studies
Related videos
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
During weight loss, bimagrumab leads to an increase in lean mass, while apitegromab slows the loss of lean mass.
Mechanism
3 studiesOne drug blocks a signal that tells muscles to stop growing, so muscles stay strong while the body loses weight. Another drug traps the signal before it can activate, achieving the same result. Both stop the body from breaking down muscle during weight loss, while still allowing fat to burn.
A drug that blocks myostatin or activin signals tells muscle cells to build more protein and stop breaking down, so muscle mass stays the same or grows even when the body is losing weight. At the same time, fat tissue breaks down more because the same signals that suppress muscle also suppress fat burning, so blocking them helps the body burn fat without losing muscle.
A monoclonal antibody binds to activin type II receptors on skeletal muscle and adipose tissue cells
Binding prevents myostatin and activin A from activating the ActRII-ALK4 pathway in skeletal muscle
Inhibition of the ActRII-ALK4 pathway removes suppression of the Akt/mTOR signaling cascade, increasing muscle protein synthesis and satellite cell activity
Inhibition of activin signaling via the ActRII-ALK7 pathway in adipose tissue enhances lipolysis and lipid mobilization
Net effect is increased muscle mass or reduced muscle breakdown during energy deficit, while fat mass decreases due to enhanced fat mobilization
Less supported by current evidence, but not ruled out
A different drug binds only to inactive myostatin before it becomes active, stopping it from ever signaling to muscle cells, which allows muscle to grow without affecting other pathways.
A monoclonal antibody selectively binds to latent myostatin precursors in circulation
Binding prevents proteolytic cleavage of myostatin into its mature, biologically active form
Mature myostatin is not available to bind ActRII receptors on muscle cells, removing inhibition of protein synthesis and satellite cell activation
Muscle mass is preserved during weight loss due to sustained anabolic signaling without systemic ActRII inhibition
Evidence from Studies
Last searched 2mo ago
Supporting (3)
Community contributions welcome
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
Bimagrumab helped people keep their muscle while losing weight, unlike other treatments that caused more muscle loss. But this study didn't test apitegromab, so we can't say how it compares.
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
The study shows that apitegromab helps people keep more muscle while losing weight, which matches part of the claim. It doesn't test bimagrumab, so we can't say for sure about that drug, but what it does show supports the part about apitegromab.
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
The study shows that bimagrumab helps people gain muscle while losing weight, which matches part of the claim. But it doesn't say anything about apitegromab, so we can't confirm that part.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Bimagrumab and Apitegromab Effects on Lean Mass During Weight Loss in Humans
Population: Adults undergoing medically supervised weight loss; Intervention: Bimagrumab; Comparator: Apitegromab and placebo; Outcome: Change in lean mass measured by DEXA or MRI; Duration: Minimum 24 weeks
Double-Blind, Placebo-Controlled Trial of Bimagrumab vs. Apitegromab on Lean Mass Preservation During Caloric Restriction
Population: Healthy adults with BMI 25–35 undergoing 12–24 weeks of 500–750 kcal/day caloric deficit; Intervention: Bimagrumab 10 mg/kg IV biweekly; Comparator: Apitegromab 10 mg/kg IV biweekly and placebo; Outcome: Change in lean mass via DEXA; Duration: 24 weeks
Prospective Cohort Study Comparing Lean Mass Trajectories in Patients Receiving Bimagrumab or Apitegromab During Weight Loss
Population: Patients prescribed bimagrumab or apitegromab during weight loss programs; Exposure: Drug administration; Comparator: Non-exposed patients receiving standard care; Outcome: Serial measurements of lean mass over 12–52 weeks; Duration: Minimum 52 weeks
Case-Control Study of Severe Lean Mass Loss in Patients Treated with Bimagrumab vs. Apitegromab During Weight Loss
Population: Patients with >5% lean mass loss (cases) vs. <1% change (controls) during weight loss; Exposure: Prior use of bimagrumab or apitegromab; Comparator: Drug exposure history; Outcome: Drug type and magnitude of lean mass change; Duration: Retrospective analysis over 1–3 years
In Vitro Analysis of Bimagrumab and Apitegromab Effects on Human Skeletal Muscle Myoblast Proliferation and Differentiation
Population: Human primary skeletal muscle myoblasts; Intervention: Exposure to bimagrumab (1–100 nM) or apitegromab (1–100 nM); Comparator: Vehicle control; Outcome: Myoblast proliferation, fusion index, and myotube size; Duration: 7–14 days